GlaxoSmithKline's once high-flying hopes in the cancer vaccine MAGE-A3 have crashed to earth--for a second time. Once a top Phase III program at the pharma giant, MAGE-A3 failed to hit a pair of primary endpoints for non-small cell lung cancer, its second ...

Gene editing pioneer Carl June at the University of Pennsylvania is back in the headlines. The academic investigator--heralded for his work on a gene editing technique now being tested for cancer--led a team of scientists who successfully used zinc finger ...